At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 84 enrolled
Drug / intervention
Litoxetine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind Randomised Placebo-Controlled Phase I/IIa Dose Titration Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine up to 30 mg vs Placebo BID in Subjects With Urinary Incontinence
In Brief
A Phase 2 clinical trial evaluating Litoxetine and placebo for Urinary Incontinence. Completed, enrolled 84 participants across 1 site.
Detailed Summary
This study will explore the safety, tolerability and efficacy of litoxetine in men and women who suffer from urinary incontinence
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Incontinence
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartApr 2018
Primary CompletionMay 2019
TodayJul 2026
First PostedJan 12, 2018
Enrollment StartApr 3, 2018
Primary CompletionMay 30, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.5 years ago
Interventions
Litoxetinedrug
oral study medication provided in a dose titration manner
placebodrug
placebo medication provided in a dose titration manner